View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports

Moody's Ratings assigns Ba1 rating to Organon's new secured credit fac...

Moody's Ratings (Moody's) assigned ratings to the proposed new debt instruments of Organon & Co. ("Organon") including a Ba1 to a new senior secured first lien term loan B, senior secured first lien revolving credit facility and secured notes, and a B1 rating to new senior unsecured notes. There are...

Organon & Co.: Modest earnings growth and debt reduction will facilita...

Our credit view of this issuer reflects its good global presence, with strong product and geographic diversity, offset by its weak growth outlook in established brands.

Moody's affirms Organon's Ba2 CFR; stable outlook

Moody's Ratings (Moody's) affirmed the ratings of Organon & Co. ("Organon") including the Ba2 Corporate Family Rating (CFR), the Ba2-PD Probability of Default Rating (PDR), the Ba2 senior secured credit facility ratings and notes, and the B1 senior unsecured rating. At the same time, Moody's upgrade...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vital Signs: Actionable charts

In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.

Organon & Co.: Top-line growth continues, but investments in business ...

Our credit view of this issuer reflects its growing biosimilars business, against its weak growth outlook in established brands.

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Valens Research
  • Valens Research

Valens Equity Insights and Inflections - 2022 05 24

Constellation Brands (STZ) has transformed its profitability profile through its massive expansion in the beer market and move to premiumization over the last seven years. Uniform Accounting highlights that the market is pricing in a reversal of recent profitability expansion and below-average growth, but management is confident about executing on their strategy and is aligned to continue to do so, signaling the potential for equity upside as the company continues executing. Constellation has c...

Valens Research
  • Valens Research

OGN - Embedded Expectations Analysis - 2022 05 17

Organon & Co. (OGN) currently trades below corporate averages relative to Uniform earnings, with a 4.5x Uniform P/E (Fwd. V/E'). At these levels, markets are pricing in expectations for Uniform ROA to fade from 49% in 2021 to 9%, accompanied by 3% Uniform asset growth. Meanwhile, analysts expect Uniform ROA to fade to 38% in 2023, accompanied by 13% Uniform asset growth. If sustained going forward, these levels would imply a stock price closer to $225, representing significant potential equit...

Organon & Co.: First year of stand-alone operating performance progres...

Our credit view of this issuer reflects its strong position in women's health, against its weak growth outlook in established brands

New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch